Drug Database
HP

HPV-16/18 (Cecolin)

✓ Approved

Beijing Wantai Biological Pharmacy · · 重组蛋白

什么是 HPV-16/18?

HPV-16/18 是一种重组蛋白,由Beijing Wantai Biological Pharmacy研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Cecolin
公司Beijing Wantai Biological Pharmacy
药物类别重组蛋白, 疫苗
分子靶点,
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

HPV-16/18 作用于 2 个分子靶点:

(E7)
(E7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

HPV-16/18 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPapilloma viral infection✓ Approved

相关研究文献

PubMedTransboundary and emerging diseases2026-11-17

Porcine Circoviruses Type 2 and 3 Chimeric Novel Vaccine Candidate Formed Virus-Like Particles and Induced Robust Immune Response in Mice.

Doan Thu-Dung TD, Pranoto Stella S, Tran Minh Tung MT, Gyawali Chet Narayan CN et al.

Porcine circovirus (PCV)-associated disease (PCVAD) encompasses a range of clinical syndromes in pigs, including wasting, reproductive failure, enteritis, and respiratory disorders. These clinical manifestations are primarily associated with PCV type 2 (PCV2). However, the recently emerged PCV type 3 (PCV3) shares limited sequence identity with PCV2, which may explain the limited cross-protection provided by current PCV2-based commercial vaccines. In this study, we developed and evaluated a novel chimeric vaccine candidate targeting both PCV2 and PCV3. A chimeric capsid protein (rCapC) was rationally designed by replacing the decoy epitope and CD-loop region of the PCV2 capsid with a type-specific epitope derived from PCV3. The recombinant protein was expressed using a baculovirus expression system and verified by sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and Western blot analysis. rCapC was predominantly detected in the insoluble fraction of Sf9 insect cell lysates and was capable of self-assembling into virus-like particles (VLPs), as confirmed by transmission electron microscopy (TEM). The antigenicity of rCapC was demonstrated by an in vitro Western blot assay, showing specific reactivity with antibodies from PCV2-infected pigs. Immunization studies in mice revealed that rCapC elicited strong and sustained humoral immune responses, persisting for up to 16 weeks post-vaccination. Notably, the chimeric protein induced antigen-specific anti-PCV2 and anti-PCV3 binding antibody responses at low antigen doses (5-25 µg per dose). These findings indicate that rCapC is a promising chimeric VLP-based vaccine candidate capable of inducing robust bivalent humoral and cellular immune responses against both PCV2 and PCV3 Cap antigens.

PMID 43042450
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →
PubMedACS nano2026-11-17

Adenovirus-Derived Virus-Like Particles Enable Rapid Encapsulation and Delivery of Functional Antigen Cargo.

Han Jiabao J, Kashentseva Elena A EA, Dmitriev Igor P IP, Lu Zhi Hong ZH et al.

Adenoviral vectors have been widely validated as effective vaccine platforms for both infectious diseases and cancer due to their strong immunostimulatory properties. However, their application to personalized cancer vaccines and other time-sensitive antigens is limited by the prolonged production time required for conventional vector generation. Here, we developed an adenovirus-derived virus-like particle (Ad5VLP) platform that enables modular incorporation of antigen cargo without reconstruction of a complete antigen-encoding adenoviral genome. Ad5VLPs successfully packaged and delivered foreign mRNA, although mRNA-derived antigen expression remained insufficient to induce robust antigen-specific immunity in vivo. In contrast, direct encapsulation of protein or peptide antigens substantially improved intracellular antigen delivery and major histocompatibility complex (MHC) class I antigen presentation. Following subcutaneous prime-boost immunization in mice, antigen-loaded Ad5VLPs induced robust antigen-specific interferon-γ (IFN-γ) responses, with functional activity preferentially enriched within CD44hi CD8+ T cells and accompanied by effector-associated CD8+ T-cell differentiation. Importantly, robust cellular immune responses were also observed using an E0771 tumor neoantigen, demonstrating that the platform extends beyond the model ovalbumin (OVA) antigen. Protein-loaded Ad5VLPs also elicited antigen-specific and antivector humoral responses. Vaccination was well tolerated over the 14 day study period, with no substantial changes in body weight, clinical observations, serum markers of hepatic or renal injury and systemic inflammation, or broad splenic inflammatory transcriptional signatures. Together, these findings demonstrate that Ad5VLPs enable modular delivery of protein and peptide antigens and induce robust cellular immune responses, supporting further investigation for personalized cancer vaccination and other time-sensitive vaccine applications.

PMID 43043202
阅读全文 →
PubMedArchives of pathology & laboratory medicine2026-11-17

Laboratory Capacity and Consideration for Use of Cervical Cancer Screening and Triage Tests: Cross-Sectional Survey Results of Laboratories Participating in the College of American Pathologists 2023 Gynecologic Cytopathology (PAP Education) Program.

Goyal Abha A, Tabbara Sana O SO, Nayar Ritu R, Souers Rhona J RJ et al.

Cervical cancer screening and management guidelines have been changing rapidly. Current screening options include cytology alone, cytology plus human papillomavirus (HPV) testing (cotesting), and primary HPV testing with reflex to cytology or p16/Ki-67 dual staining, or with extended genotyping. To understand laboratory practices around test(s) offered for cervical cancer screening and triage modalities for positive HPV test results. The College of American Pathologists invited 1432 laboratories (participating in the PAP Education program) to complete a supplemental questionnaire in one of their 2023 educational mailings. Overall, 532 questionnaires were completed (387 domestic, 145 international). Among the 387 domestic laboratories, 89.7% (347) offered cotesting, 88.9% (344) offered cytology (with reflex HPV testing for "atypical squamous cell of undetermined significance"), and 16.0% (62) offered primary HPV testing (with reflex cytology). US Food and Drug Administration (FDA)-approved primary HPV platforms were available in 45% (108 of 240) of laboratories (Roche cobas: 41.7% [100]; BD Onclarity: 3.3% [8]). Main reasons for not offering HPV screening included not having an FDA-approved platform, and limited clinician requests. Partial HPV genotyping (HPV 16/18 ± HPV 45) was offered by 54.6% (206 of 377) and p16/Ki-67 dual staining by 6.3% (23 of 361) of laboratories. Utilization of primary HPV screening by laboratories may be limited by access to FDA-approved testing platforms and limited client demand. Since this survey completion, Enduring Guidelines recommendations have been published for use of self-collected HPV testing and different triage modalities. Future surveys to assess the laboratories' response to evolving screening and management guidelines are warranted.

PMID 43042927
阅读全文 →
PubMedFrontiers in oncology2026-11-17

Impact of cervical cancer education on knowledge, attitudes and preventive practices among adolescent girls in secondary schools: a scoping review.

Jolayemi Karimat Itunu KI, Esan Deborah Tolulope DT, Akingbade Oluwadamilare O, Ogunmuyiwa Ayodeji Olubunmi AO et al.

Cervical cancer remains one of the most preventable yet deadliest cancers affecting women in Africa. Despite global advances in prevention through human papillomavirus (HPV) vaccination, screening, and early treatment, Sub-Saharan Africa continues to experience disproportionately high incidence and mortality rates because of limited health infrastructure, inadequate awareness, and delayed diagnosis. Given that adolescence represents a critical window for establishing lifelong health behaviors, school-based cervical cancer education may provide an effective platform for improving knowledge and promoting preventive practices in line with the World Health Organization's (WHO) cervical cancer elimination strategy. This review was conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews and reported following the PRISMA-ScR guidelines. A comprehensive search of PubMed, Scopus, Web of Science, CINAHL, African Journals Online (AJOL), the Cochrane Library, and Google Scholar was undertaken for studies published up to 2026. A total of 1,700 records were identified and screened, resulting in the inclusion of 20 eligible studies. Data were extracted, charted, and synthesized using a narrative approach. Evidence suggests that baseline knowledge of cervical cancer and HPV among adolescent girls in African secondary schools remains generally low to moderate. A consistent knowledge-attitude gap was identified, whereby positive attitudes toward prevention frequently coexisted with limited factual understanding of cervical cancer risk factors, screening, and HPV vaccination. Educational interventions, including peer-led programmes, classroom-based teaching, health campaigns, and multimodal educational strategies, consistently produced significant improvements in knowledge and awareness. However, improvements were less pronounced for more complex concepts, including disease curability, recommended screening intervals, and vaccine mechanisms. Furthermore, an intention-behavior gap was observed, as high levels of vaccine acceptance rarely translated into actual uptake because of parental, sociocultural, and health system barriers. Geographical analysis revealed a substantial concentration of studies in a limited number of Anglophone countries, particularly Nigeria, Ghana, Ethiopia, Kenya, and Uganda, highlighting important gaps in evidence across many African settings. School-based cervical cancer education represents a feasible and scalable strategy for improving cervical cancer literacy among African adolescents. However, achieving the WHO's cervical cancer elimination targets will require a shift from isolated educational sessions toward sustainable, curriculum-integrated, multilevel interventions involving schools, families, healthcare providers, and policymakers. Future research should prioritize the evaluation of long-term behavioral outcomes, particularly HPV vaccine uptake and participation in cervical cancer screening programmes.

PMID 43041686
阅读全文 →
PubMedJNCI cancer spectrum2026-11-17

HPV prevalence and risk factors in a population-based cervical cancer screening program in Tashkent, Uzbekistan.

Turabova Nozimakhon Rakhmatullakhodjaevna NR, Akhmedova Lyubov Mikhaylovna LM, Akhmedova Shakhnoza Khayrullaevna SK, Mirkasimova Kholida Khafizovna KK et al.

Population-based evidence on high-risk human papillomavirus (hrHPV) and cervical screening outcomes in Uzbekistan is limited. We assessed hrHPV prevalence, district variation, associated factors, and cytological findings in Tashkent. A cross-sectional study was conducted among 52,995 women aged 18-70 years attending routine cervical screening across Tashkent city during 2024-2025. HR-HPV testing was performed using real-time PCR; reflex liquid-based cytology was performed for all HPV-positive women. Multivariable logistic regression was used to identify independent determinants of HPV positivity (n = 52,995) and cytological abnormality (n = 2,255 HPV-positive women with adequate cytology). Overall HR-HPV positivity was 4.43% (95% CI: 4.26-4.61%), with significant heterogeneity across districts (p < 0.01); Bektemir district recorded the highest prevalence. Independent predictors of HPV positivity included older age (aOR 2.41, 95% CI 1.24-4.83, for 56-70 years), irregular menstruation (aOR 1.39, 95% CI 1.23-1.57), and early sexual debut, while barrier contraception (aOR 0.70, 95% CI 0.60-0.81) and grand multiparity (aOR 0.80, 95% CI 0.65-0.98) were protective. Among HPV-positive women, any cytological abnormality was detected in 24.6% and high-grade lesions in 17.3%. Keratosis was the strongest predictor of cytological abnormality (aOR 4.09-5.16, both p < 0.01). This large population-based study establishes a comprehensive HPV epidemiological baseline for Tashkent and demonstrates the clinical yield of HPV-primary screening with reflexive cytology triage. District-level heterogeneity and identified risk profiles provide evidence for geographically targeted program optimization in support of Uzbekistan's progress toward WHO 90-70-90 cervical cancer elimination targets.

PMID 43040636
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多HPV-16/18